VIM and neoplasm: We assessed circulating tumor cell subsets expressing cancer stem cell markers (CD90, epithelial cell adhesion molecule, CD133, vimentin) using multiparametric flow cytometry at early and maximal response phases in patients receiving atezolizumab plus bevacizumab or lenvatinib.